258 related articles for article (PubMed ID: 15213599)
1. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
2. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
3. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis.
Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H
Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159
[TBL] [Abstract][Full Text] [Related]
5. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Kato N; Watanabe J; Jobo T; Nishimura Y; Fujisawa T; Kamata Y; Kuramoto H
J Cancer Res Clin Oncol; 2003 Apr; 129(4):222-6. PubMed ID: 12684894
[TBL] [Abstract][Full Text] [Related]
7. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
8. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
9. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma.
Kamata Y; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Hattori M; Obokata A; Kuramoto H
J Cancer Res Clin Oncol; 2005 Sep; 131(9):591-6. PubMed ID: 16080017
[TBL] [Abstract][Full Text] [Related]
10. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.
Feng YZ; Shiozawa T; Horiuchi A; Shih HC; Miyamoto T; Kashima H; Suzuki A; Nikaido T; Konishi I
Virchows Arch; 2005 Nov; 447(5):816-22. PubMed ID: 16021509
[TBL] [Abstract][Full Text] [Related]
12. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
Buchynska LG; Nesina IP; Kashuba EV
Exp Oncol; 2007 Dec; 29(4):287-94. PubMed ID: 18199985
[TBL] [Abstract][Full Text] [Related]
13. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
14. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
15. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.
Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P
Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603
[TBL] [Abstract][Full Text] [Related]
16. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG
Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224
[TBL] [Abstract][Full Text] [Related]
17. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas.
Shiozawa T; Xin L; Nikaido T; Fujii S
Int J Gynecol Pathol; 1997 Oct; 16(4):348-53. PubMed ID: 9421074
[TBL] [Abstract][Full Text] [Related]
19. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters.
Watanabe J; Sato H; Kanai T; Kamata Y; Jobo T; Hata H; Fujisawa T; Ohno E; Kameya T; Kuramoto H
Br J Cancer; 2002 Jul; 87(1):81-5. PubMed ID: 12085261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
